Clinical trial · Observational
GlowCap Reminder System in Patients With Early Stage Breast Cancer Receiving Adjuvant Endocrine Therapy
Feasibility of Using the GlowCap Reminder System in Patients With Early Stage Breast Cancer Receiving Adjuvant Endocrine Therapy
NCT01239251CI-TRIAL-00017060terminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to test the ease of using a new device, called the GlowCap that reminds the patient to take their breast cancer hormone pill. The study will collect information about the experience with this device and what the patient thinks of its role in the daily pill taking routine.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| GlowCap device | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- breast cancer patients taking endocrine therapy
- description
- Breast cancer patients, currently taking adjuvant endocrine therapy will be equipped with a GlowCap device for a period of 30 days. The GlowCap will become part of their medication taking routine.
- interventionNames
- Other: GlowCap device
Primary outcomes (1)
- measure
- Assess the usability of the GlowCap system by patients
- timeFrame
- 2 years
- description
- \>60 years of age with early stage breast cancer.
Secondary outcomes (1)
- measure
- Measure the acceptance and satisfaction of the GlowCap reminder system
- timeFrame
- 2 years
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Early stage breast cancer patients taking adjuvant endocrine therapy (ie, tamoxifen, anastrozole, letrozole, exemestane). * Age ≥ 60 years * Must have broadband internet access at home (to enable the base for the system to communicate to the Vitality server). * Must have a landline or mobile phone Exclusion Criteria: * Non-English speaking patients
References
Publications (0)
Data not yet available
No reference posted for this study.